Peer Review History

Original SubmissionMay 26, 2024
Decision Letter - Deepak Dhamnetiya, Editor

PONE-D-24-21194Incidence trends of gastric cancer in the United States over 2000-2020: A population-based analysisPLOS ONE

Dear Dr. Nejadghaderi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 31 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Deepak Dhamnetiya, MD

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Major Revisions

01. The federal Public Health Emergency for COVID-19 in the US was expired on May 11, 2023. As the study uses data till 2020, the effects of COVID-19 pandemic can’t be correctly evaluated.

02. Please correct reference number 4 and add the date of access as on 24th June, 2024 the rate is 36.4%

03. In page 5 the authors state: “Moreover, past research has not assessed the impact of the COVID-19 pandemic on the occurrence of gastric cancer (16, 17).”

The studies referred to were both conducted before 2020. How can the assess the impact of COVID-19 pandemic? Please rewrite this sentence.

04. Page 09: “Adenocarcinoma was the most common subtype (72.38%) in this age group.”

I could not find it in Table 1. Please add “not shown in the table” if it is not mentioned.

05. Same page: “Also, most patients were males (60.94%) and NHWs (65.82%).”

The male and female percentage does not add up to 100% and the male % is 49.86%. Please restructure table 01 to make more understandable.

06. Page 10: “Most of the cases were adenocarcinoma (74.41%)”.

I could not find it in Table 1. Please add “not shown in the table” if it is not mentioned.

07. Page 18: “Furthermore, COVID-19 led to a significant decrease in the ASIRs of gastric cancer in the US.”

Is it due to COVID-19 Pandemic or due to reporting issues? Please clarify.

08. In page 19 the authors mentioned “Despite the lower incidence of gastric cancer in the US compared to the global values, its five-year survival rate is less than 30%” which is in contrast with the earlier statement “…the survival rates for gastric cancer

remain suboptimal, with a five-year survival rate of 35.7% in the US” in page 04. Please correct this.

09. Author contribution:

Please revise as AS, AE, ZY, RMA may not fulfill the ICJME criteria.

Minor Revisions

01. Continuous line numbers should have been used in the manuscript as recommended by the journal

02. Please rephrase the statement for better understanding: “Histologically, they are classified into adenocarcinoma (accounts for approximately 90% of gastric cancers), which itself is comprised of tubular, papillary, mucinous, and poorly cohesive subtypes, in addition to other relatively rare histologic variants like gastrointestinal stromal tumors (GISTs), lymphoma, and carcinoid tumors.”

03. Page 10: “Many cases occurred in men (57.80%) and NHWs (47.04%).”

Please rewrite this line and avoid words like “many”.

04. Page 20: “In addition to the advances,

detection and treatment of H. pylori and endoscopic screening for the native and especially the

minority populations in the US are highly recommended (52).”

As the study did not consider the native and minority populations separately, can such statement be made? I recommend removing this line.

05. Page 23: “Furthermore, severe acute

respiratory syndrome coronavirus two…”

the "two" should be 2.

Reviewer #2: Please eleborate on the methods and discussion section. Also, please give a rationale, as to why this secondary analysis was done and what addition to the existing literature does this analysis bring. Use logical models and do not overarch the interpretation in the discussion.

Reviewer #3: The articles is written in a scientifically sound fashion, the title corresponds with methodology used to achieve the objective of the study. There is tittle Ethical issue as the data was generated using publicly available secondary data following sponsors' guideline. The results are correct statistically and were discussed in an intelligent manner.

The article should be accepted for publication.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Abdulrahman Ahmad

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to Reviewers:

Manuscript reference number: PONE-D-24-21194

Title: Incidence trends of gastric cancer in the United States over 2000-2020: A population-based analysis

Dear Dr. Dhamnetiya,

Thank you for giving us the opportunity to revise our paper for potential publication in PLOS ONE. We are grateful to the reviewers and the Editors for their constructive and positive comments on our paper. We have addressed each of the comments in our revision, which has further improved the article. Below we detail our changes and respond to each of the comments in turn.

Journal requirements

When submitting your revision, we need you to address these additional requirements.

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Response: Thank you. We checked the guidelines and revised the manuscript accordingly.

2. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

Response: The data availability statement was amended accordingly.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: We only provided the ethics statement in the Methods.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: The captions for Supporting Information files were added in the manuscript.

Reviewer Comments to Author:

Reviewer: 1

Comments to Author

Major Revisions

01. The federal Public Health Emergency for COVID-19 in the US was expired on May 11, 2023. As the study uses data till 2020, the effects of COVID-19 pandemic can’t be correctly evaluated.

Response: Thank you so much for your time and your valuable feedback. We acknowledge that our data collection concludes in 2020, which limits our ability to fully evaluate the long-term effects of the COVID-19 pandemic on gastric cancer incidence. Our objective was to provide preliminary observations on the immediate impact of the pandemic within the available timeframe. We have noted this limitation in our discussion and clarified that the observed decline in 2020 may be influenced by factors related to the pandemic, such as delays in diagnosis and treatment, rather than a true decrease in incidence. Future studies with more extended post-pandemic data will be necessary to accurately assess the long-term effects of COVID-19 on gastric cancer trends. We provided the explanations in the last paragraph of Discussion.

02. Please correct reference number 4 and add the date of access as on 24th June, 2024 the rate is 36.4%

Response: It was updated accordingly.

03. In page 5 the authors state: “Moreover, past research has not assessed the impact of the COVID-19 pandemic on the occurrence of gastric cancer (16, 17).”

The studies referred to were both conducted before 2020. How can the assess the impact of COVID-19 pandemic? Please rewrite this sentence.

Response: We want to highlight that no similar studies used the recent data to evaluate the effects of COVID-19 pandemic on incidence trends of gastric cancer by age, sex, and race. The cited references are those recent relevant articles on this topic that did not evaluate the COVID-19 pandemic. We rewrote the sentence for clarification.

04. Page 09: “Adenocarcinoma was the most common subtype (72.38%) in this age group.”

I could not find it in Table 1. Please add “not shown in the table” if it is not mentioned.

Response: The ratios provided in the tables are all calculated using the race-specific population as the denominator, regardless of the age range. However, it's important to note that in the manuscript, for any age-specific ratio, both race and age-specific populations were used as the denominator, as accurately mentioned. As it was not shown in the table, we clarified it in the text.

05. Same page: “Also, most patients were males (60.94%) and NHWs (65.82%).”

The male and female percentage does not add up to 100% and the male % is 49.86%. Please restructure table 01 to make more understandable.

Response: The gender ratios in the table were calculated by dividing the age-specific sex values by the total population of the corresponding sex, however in the manuscript in order to calculate the age-specific sex ratio, only age-specific population was used. This is the reason for the confusion.

We used the following formula in the table for each entry:

We used the following formula for age-specific entries in the manuscript:

In similar fashion, in the manuscript in order to calculate the age specific racial ratio only age specific population was used.

06. Page 10: “Most of the cases were adenocarcinoma (74.41%)”.

I could not find it in Table 1. Please add “not shown in the table” if it is not mentioned.

Response: We provided further details about its calculation in the manuscript in the previous comment and it was clarified that it was not shown in the table, in the main text.

07. Page 18: “Furthermore, COVID-19 led to a significant decrease in the ASIRs of gastric cancer in the US.”

Is it due to COVID-19 Pandemic or due to reporting issues? Please clarify.

Response: It may be attributed to multiple factors related to the COVID-19 pandemic. These factors include disruptions in healthcare services, such as reduced access to routine screenings and diagnostic procedures, as well as delays in seeking medical attention due to lockdowns and fear of contracting the virus. Additionally, reporting issues and temporary reallocation of healthcare resources towards managing the pandemic may have contributed to the apparent decline in reported cases. The explanations were provided in the first paragraph of Discussion.

08. In page 19 the authors mentioned “Despite the lower incidence of gastric cancer in the US compared to the global values, its five-year survival rate is less than 30%” which is in contrast with the earlier statement “…the survival rates for gastric cancer

remain suboptimal, with a five-year survival rate of 35.7% in the US” in page 04. Please correct this.

Response: Thank you. It was corrected.

09. Author contribution:

Please revise as AS, AE, ZY, RMA may not fulfill the ICJME criteria.

Response: Per journal guidelines (https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf), we removed this section and just provided the contribution of each author in the submission site. We considered this point in the revision.

Minor Revisions

01. Continuous line numbers should have been used in the manuscript as recommended by the journal

Response: It was added.

02. Please rephrase the statement for better understanding: “Histologically, they are classified into adenocarcinoma (accounts for approximately 90% of gastric cancers), which itself is comprised of tubular, papillary, mucinous, and poorly cohesive subtypes, in addition to other relatively rare histologic variants like gastrointestinal stromal tumors (GISTs), lymphoma, and carcinoid tumors.”

Response: To improve clarity, we will rephrase the statement as follows:

"Histologically, gastric cancers are primarily classified into adenocarcinoma, which accounts for approximately 90% of cases. Adenocarcinoma itself has several subtypes, including tubular, papillary, mucinous, and poorly cohesive types. In addition to adenocarcinoma, there are other less common histologic variants such as gastrointestinal stromal tumors (GISTs), lymphomas, and carcinoid tumors".

03. Page 10: “Many cases occurred in men (57.80%) and NHWs (47.04%).”

Please rewrite this line and avoid words like “many”.

Response: We revised the sentence to:

"A total of 57.80% of cases occurred in men and 47.04% occurred in NHWs".

04. Page 20: “In addition to the advances,

detection and treatment of H. pylori and endoscopic screening for the native and especially the

minority populations in the US are highly recommended (52).”

As the study did not consider the native and minority populations separately, can such statement be made? I recommend removing this line.

Response: As recommended, we removed the sentence.

05. Page 23: “Furthermore, severe acute

respiratory syndrome coronavirus two…”

the "two" should be 2.

Response: It was corrected.

Reviewer: 2

Comments to Author

Please eleborate on the methods and discussion section. Also, please give a rationale, as to why this secondary analysis was done and what addition to the existing literature does this analysis bring. Use logical models and do not overarch the interpretation in the discussion.

Response: Thank you so much for your time and your valuable comments. We provided the rationale for this study and how the findings might be helpful for health policymakers in the last paragraph of Introduction. We also expanded Methods and Discussion by providing further details about the methodology and statistical tests performed in the study.

Reviewer: 3

Comments to Author

The articles is written in a scientifically sound fashion, the title corresponds with methodology used to achieve the objective of the study. There is tittle Ethical issue as the data was generated using publicly available secondary data following sponsors' guideline. The results are correct statistically and were discussed in an intelligent manner.

The article should be accepted for publication.

Response: Thank you so much for your kind words and positive feedback on our manuscript. As it was mentioned in the Methods section, the access to the SEER data was in accordance with the SEER data agreement and after approval of the relevant guidelines.

Attachments
Attachment
Submitted filename: RTR PLOS ONE-Gastric Cancer SEER.doc
Decision Letter - Deepak Dhamnetiya, Editor

Incidence trends of gastric cancer in the United States over 2000-2020: A population-based analysis

PONE-D-24-21194R1

Dear Dr. Nejadghaderi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Deepak Dhamnetiya, MD

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing all my comments. The manuscript can be published now. I recommend publication.

Reviewer #2: Thank you for making the requested changes by the reviewers. The manuscript is in better shape now and can be published.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Aftab Ahmad

**********

Formally Accepted
Acceptance Letter - Deepak Dhamnetiya, Editor

PONE-D-24-21194R1

PLOS ONE

Dear Dr. Nejadghaderi,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Deepak Dhamnetiya

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .